Key Takeaway: Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced its participation in the 45th Annual TD Cowen Health Care Conference scheduled for March 4, 2025. The presentation will be accessible via live webcast and will include a replay option afterward. Madrigal focuses on innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH), with its leading therapeutic candidate, Rezdiffra, aimed at addressing this liver disease.
Price reaction · baseline $351.03 (2025-02-20 close) · hit after-hours · 2 other MDGL headline(s) in the window, move may be shared
day 0 close · peak
-4.2%
Market Sentiment Analysis
POSITIVE FACTORS
Madrigal Pharmaceuticals will showcase its commitment at a major healthcare conference.
The company's product, Rezdiffra, targets a significant unmet need in liver disease.
The presentation offers an opportunity for investor engagement and visibility.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+125%
120-day peak, hindsight
Typical move
4.2%
average across 7 past catalysts
Cash runway
~45 mo
Minimal dilution risk
Lead asset
Resmetirom
Phase 3 · Non-Alcoholic Fatty Liver Disease
Full Press Release Details
CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET.
The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page. A replay of the webcast will be available after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. For more information, visit www.madrigalpharma.com.
Frequently Asked Questions
When will Madrigal Pharmaceuticals participate in the TD Cowen Conference?
Madrigal Pharmaceuticals will participate on March 4, 2025, at 11:10 A.M. ET.
How can I access the Madrigal Pharmaceuticals presentation?
The presentation will be webcast live and accessible via Madrigal’s website.
What is Madrigal Pharmaceuticals' focus area?
Madrigal focuses on developing therapies for metabolic dysfunction-associated steatohepatitis.
What is Rezdiffra (resmetirom)?
Rezdiffra is a once-daily, oral medication targeting causes of metabolic liver diseases.
Where can I find more information about Madrigal Pharmaceuticals?
For more information, visit Madrigal Pharmaceuticals' official website at www.madrigalpharma.com.